Masaaki Oka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Masaaki Oka has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
Shigefumi Yoshino
38 shared publications- Shoichi Hazama
Department of Surgery, Gastroenterological Center, Shunan Memorial Hospital, Kudamatsu, Yamaguchi, Japan
38 shared publications Kazuhiko Sakamoto
16 shared publicationsTomio Ueno
14 shared publications- Kiyoshi Yoshimura
Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755‑8505, Japan
11 shared publications Takao Tamesa
11 shared publications
Latest Publications
- Open Access
- 28 February 2017
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 36 (1) , 1-10
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
The purpose of the present study was to explore novel biomarkers that can predict the clinical outcome of patients before treatment or during vaccination. These would be useful for the selection of appropriate patients who would be expected to exhibit better treatment outcomes from vaccination, and for facilitating the development of cancer vaccine treatments. From a single-arm, non-randomized, human leukocyte antigen (HLA)-A-status-blind phase II trial of a vaccine treatment using three HLA-A*2402-restricted peptides for advanced pancreatic cancer (PC), we obtained peripheral blood samples from 36 patients of an HLA-A*2402-matched group and 27 patients of an HLA-A*2402-unmatched group. Multivariate analysis (HR = 2.546; 95% CI = 1.138 to 5.765; p = 0.0231) and log-rank test (p = 0.0036) showed that a high expression level of programmed death-1 (PD-1) on CD4+ T cells was a negative predictive biomarker of overall survival in the HLA-A*2402-matched group . Moreover, a high expression level of PD-1 on CD4+ T cells was a negative predictor for the induction of cytotoxic T lymphocytes (p = 0.0007). After treatment, we found that the upregulation of PD-1 and T cell immunoglobulin mucin-3 (Tim-3) expression on CD4+ and CD8+ T cells was significantly associated with a poor clinical outcome in the HLA-A*2402-matched group (p = 0.0330, 0.0282, 0.0046, and 0.0068, respectively). In contrast, there was no significant difference for these factors in the HLA-A*2402-unmatched group. Our results indicate that the upregulation of PD-1 and Tim-3 expression on CD4+ and CD8+ T cells may restrict T cell responses in advanced PC patients; therefore, combination immunotherapy with blockade of PD-1 and Tim-3 to restore T cell responses may be a potential therapeutic approach for advanced PC patients. Clinical-Trail-Registration: UMIN000008082 .
- 28 February 2017
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 36 (1) , 1-10
Open AccessPredictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
The purpose of the present study was to explore novel biomarkers that can predict the clinical outcome of patients before treatment or during vaccination. These would be useful for the selection of appropriate patients who would be expected to exhibit better treatment outcomes from vaccination, and for facilitating the development of cancer vaccine treatments. From a single-arm, non-randomized, human leukocyte antigen (HLA)-A-status-blind phase II trial of a vaccine treatment using three HLA-A*2402-restricted peptides for advanced pancreatic cancer (PC), we obtained peripheral blood samples from 36 patients of an HLA-A*2402-matched group and 27 patients of an HLA-A*2402-unmatched group. Multivariate analysis (HR = 2.546; 95% CI = 1.138 to 5.765; p = 0.0231) and log-rank test (p = 0.0036) showed that a high expression level of programmed death-1 (PD-1) on CD4+ T cells was a negative predictive biomarker of overall survival in the HLA-A*2402-matched group . Moreover, a high expression level of PD-1 on CD4+ T cells was a negative predictor for the induction of cytotoxic T lymphocytes (p = 0.0007). After treatment, we found that the upregulation of PD-1 and T cell immunoglobulin mucin-3 (Tim-3) expression on CD4+ and CD8+ T cells was significantly associated with a poor clinical outcome in the HLA-A*2402-matched group (p = 0.0330, 0.0282, 0.0046, and 0.0068, respectively). In contrast, there was no significant difference for these factors in the HLA-A*2402-unmatched group. Our results indicate that the upregulation of PD-1 and Tim-3 expression on CD4+ and CD8+ T cells may restrict T cell responses in advanced PC patients; therefore, combination immunotherapy with blockade of PD-1 and Tim-3 to restore T cell responses may be a potential therapeutic approach for advanced PC patients. Clinical-Trail-Registration: UMIN000008082 .
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S37
Development of suture-assistance devices that facilitate pancreaticojejunostomy: Outcomes of early clinical study
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S37
Development of suture-assistance devices that facilitate pancreaticojejunostomy: Outcomes of early clinical study
- 1 October 2015
- Vol. 42 (10) , 1310-2
[Relationship between Polymorphisms and the Efficacy of Cetuximab].
Cetuximab has shown efficacy in patients with metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC), mediated via the fragment c gamma receptors(FcgR)in mCRC. Since the establishment of KRAS mutations as a major negative predictor of efficacy, additional biomarkers have been found to be useful for the improvement of selection of patients likely to be responsive to cetuximab. We investigated the relationship between polymorphisms and the outcome of mCRC patients treated with cetuximab. In this study, 57 patients were evaluated. The relationships of FcgR polymorphisms with response rate (RR), progression-free survival (PFS), and overall survival (OS) were analyzed. The FcgR polymorphisms were not significantly related to RR, PFS, and OS. Compared with the other haplotypes, the haplotype containing the 131H and 158V alleles was related to a lower RR (p=0.018). The diplotypes containing 131H and 158V alleles had significantly lower RR than the other diplotypes (p=0.038). Our data suggest that FcgR polymorphisms may be associated with the outcome of mCRC patients treated with cetuximab and FOLFIRI. However, these results are currently controversial, and detailed investigations are needed to confirm the relationship between FcgRs polymorphisms and cetuximab efficacy.
- 1 October 2015
- Vol. 42 (10) , 1310-2
[Relationship between Polymorphisms and the Efficacy of Cetuximab].
Cetuximab has shown efficacy in patients with metastatic colorectal cancer (mCRC). Recent studies have demonstrated that cetuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC), mediated via the fragment c gamma receptors(FcgR)in mCRC. Since the establishment of KRAS mutations as a major negative predictor of efficacy, additional biomarkers have been found to be useful for the improvement of selection of patients likely to be responsive to cetuximab. We investigated the relationship between polymorphisms and the outcome of mCRC patients treated with cetuximab. In this study, 57 patients were evaluated. The relationships of FcgR polymorphisms with response rate (RR), progression-free survival (PFS), and overall survival (OS) were analyzed. The FcgR polymorphisms were not significantly related to RR, PFS, and OS. Compared with the other haplotypes, the haplotype containing the 131H and 158V alleles was related to a lower RR (p=0.018). The diplotypes containing 131H and 158V alleles had significantly lower RR than the other diplotypes (p=0.038). Our data suggest that FcgR polymorphisms may be associated with the outcome of mCRC patients treated with cetuximab and FOLFIRI. However, these results are currently controversial, and detailed investigations are needed to confirm the relationship between FcgRs polymorphisms and cetuximab efficacy.
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 619
Multicenter trial for assessing cytokine promoter gene polymorphism as a predictive parameter of PSK responder for curatively resected stage II or III colorectal cancer.
619 Background: Polysaccharide-K (PSK), a protein-bound polysaccharide extracted from the mycelia of Coriolus versicolor, is an immunomodulator widely used in colorectal cancer in Japan. PSK has immunological actions including enhancement or inhibition of cytokine production. It has been reported that levels of cytokine production are influenced by polymorphisms in the promoters of cytokine genes. We hypothesized that cytokine promoter gene polymorphisms may be responsible for genetic susceptibilities to immunological effect of PSK. Methods: This is a multicenter prospective trial. One hundred and ten patients with stage II or III colorectal cancer were enrolled. All patients received adjuvant immnochemotherapy after curative resection using UFT (stage II) or UFT/LV (stage III) combined with PSK (3.0 g/day, p.o.) for 1 year. Post-operative survey of recurrence was followed with CT scan at 6-month intervals during the first 2 years after surgery and at 1-year intervals thereafter until 5 year after surgery. DNA was extracted from peripheral blood cells in all patients. The following polymorphisms of the patients were genotyped: TNF-α-1031T/C, IL-1ß-511C/T, IL-6-634C/G, IL-10-819T/C. Results: Twenty (6 in stage II, 14 in stage III) out of 110 patients showed recurrence after more than 5 years survey. Fifteen out of 74 patients with TNF-α-1031 TT genotype and 5 out of 36 with TNF-α-1031 CC or CT showed disease recurrence. Five out of 39 patients with IL-1ß-511 CC and 15 out of 71 with IL-1ß-511 CT or TT showed disease recurrence. Eleven out of 61 patients with IL-6-634 CC and 9 out of 49 with IL-6-634 CG or GG showed disease recurrence. No association between genotype frequency and disease recurrence was observed for TNF-α, IL-1ß, IL-6. Fifteen out of 61 patients with IL-10-819 CC or CT genotype showed disease recurrence, whereas only 5 out of 49 with IL-10-819 TT showed tumor recurrence (p=0.052). Especially, significant association with disease recurrence was found in stage III patients (12/30 vs 2/17, p=0.042). Conclusions: It is suggested that colorectal cancer patients with IL-10-819 TT genotype could be PSK responder after curative resection.
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 619
Multicenter trial for assessing cytokine promoter gene polymorphism as a predictive parameter of PSK responder for curatively resected stage II or III colorectal cancer.
619 Background: Polysaccharide-K (PSK), a protein-bound polysaccharide extracted from the mycelia of Coriolus versicolor, is an immunomodulator widely used in colorectal cancer in Japan. PSK has immunological actions including enhancement or inhibition of cytokine production. It has been reported that levels of cytokine production are influenced by polymorphisms in the promoters of cytokine genes. We hypothesized that cytokine promoter gene polymorphisms may be responsible for genetic susceptibilities to immunological effect of PSK. Methods: This is a multicenter prospective trial. One hundred and ten patients with stage II or III colorectal cancer were enrolled. All patients received adjuvant immnochemotherapy after curative resection using UFT (stage II) or UFT/LV (stage III) combined with PSK (3.0 g/day, p.o.) for 1 year. Post-operative survey of recurrence was followed with CT scan at 6-month intervals during the first 2 years after surgery and at 1-year intervals thereafter until 5 year after surgery. DNA was extracted from peripheral blood cells in all patients. The following polymorphisms of the patients were genotyped: TNF-α-1031T/C, IL-1ß-511C/T, IL-6-634C/G, IL-10-819T/C. Results: Twenty (6 in stage II, 14 in stage III) out of 110 patients showed recurrence after more than 5 years survey. Fifteen out of 74 patients with TNF-α-1031 TT genotype and 5 out of 36 with TNF-α-1031 CC or CT showed disease recurrence. Five out of 39 patients with IL-1ß-511 CC and 15 out of 71 with IL-1ß-511 CT or TT showed disease recurrence. Eleven out of 61 patients with IL-6-634 CC and 9 out of 49 with IL-6-634 CG or GG showed disease recurrence. No association between genotype frequency and disease recurrence was observed for TNF-α, IL-1ß, IL-6. Fifteen out of 61 patients with IL-10-819 CC or CT genotype showed disease recurrence, whereas only 5 out of 49 with IL-10-819 TT showed tumor recurrence (p=0.052). Especially, significant association with disease recurrence was found in stage III patients (12/30 vs 2/17, p=0.042). Conclusions: It is suggested that colorectal cancer patients with IL-10-819 TT genotype could be PSK responder after curative resection.
- 1 November 2014
- Vol. 41 (12) , 1500-2
[Clinical benefit of thoracoscopic approach for liver tumors located under the diaphragm].
It is important to ensure restricted operation fields and operation maneuvers in the surgical resection of liver tumors located under the diaphragm, especially those near the hepatic vein and IVC. Here we describe resection and ablation using thoracoscopy for tumors under the diaphragm after preoperative three-dimensional (3D) simulation. Preoperative 3D images were reformatted preoperatively using a 3D software tool (Virtual Place; AZE, Japan). These images simulate the thoracoscopic view on the surface of the diaphragm, enabling us to confirm the tumor location and choose optimal port position. We performed thoracoscopic surgery in 5 patients (4 with HCC and 1 with a metastatic tumor) after the simulation. In all cases, we were able to safely confirm the tumor locations and perform the surgeries. Preoperative 3D simulation makes it easy to determine the optimal port position for the thoracoscope and confirm the tumor location. The approach through the diaphragm using thoracoscpy is useful since it does not require liver mobilization.
- 1 November 2014
- Vol. 41 (12) , 1500-2
[Clinical benefit of thoracoscopic approach for liver tumors located under the diaphragm].
It is important to ensure restricted operation fields and operation maneuvers in the surgical resection of liver tumors located under the diaphragm, especially those near the hepatic vein and IVC. Here we describe resection and ablation using thoracoscopy for tumors under the diaphragm after preoperative three-dimensional (3D) simulation. Preoperative 3D images were reformatted preoperatively using a 3D software tool (Virtual Place; AZE, Japan). These images simulate the thoracoscopic view on the surface of the diaphragm, enabling us to confirm the tumor location and choose optimal port position. We performed thoracoscopic surgery in 5 patients (4 with HCC and 1 with a metastatic tumor) after the simulation. In all cases, we were able to safely confirm the tumor locations and perform the surgeries. Preoperative 3D simulation makes it easy to determine the optimal port position for the thoracoscope and confirm the tumor location. The approach through the diaphragm using thoracoscpy is useful since it does not require liver mobilization.
- 1 November 2014
- Vol. 41 (12) , 2352-4
[A case of metachronous liver metastasis from gastric cancer successfully treated with hepatectomy].
The use of hepatectomy for the treatment of liver metastasis from gastric cancer has been controversial. We report a case of metachronous liver metastasis from gastric cancer, which we successfully treated with hepatectomy. A 59-year-old man underwent laparoscopy-assisted total gastrectomy with D1 plus lymphadenectomy for gastric cancer. The histopathological findings revealed that the tumor was a well-differentiated tubular adenocarcinoma, T2(MP), N1(#1 2/3), M0, fStage II, according to the 14th edition of the Japanese Classification of Gastric Carcinoma. TS-1 was administered as adjuvant chemo- therapy for 1 year after the operation. About 5 years after the gastrectomy, a recurrent tumor was detected in S5/8-7 of the liver. Although chemotherapy with TS-1 plus Lentinan was administered, the liver tumor increased in size. Percutaneous transhepatic portal embolization was performed to improve liver function followed by resection of the right lobe of the liver. Paclitaxel plus doxifluridine (5'-DFUR) was administered for 6 months as adjuvant chemotherapy. No recurrence was observed for 17 months after hepatectomy.
- 1 November 2014
- Vol. 41 (12) , 2352-4
[A case of metachronous liver metastasis from gastric cancer successfully treated with hepatectomy].
The use of hepatectomy for the treatment of liver metastasis from gastric cancer has been controversial. We report a case of metachronous liver metastasis from gastric cancer, which we successfully treated with hepatectomy. A 59-year-old man underwent laparoscopy-assisted total gastrectomy with D1 plus lymphadenectomy for gastric cancer. The histopathological findings revealed that the tumor was a well-differentiated tubular adenocarcinoma, T2(MP), N1(#1 2/3), M0, fStage II, according to the 14th edition of the Japanese Classification of Gastric Carcinoma. TS-1 was administered as adjuvant chemo- therapy for 1 year after the operation. About 5 years after the gastrectomy, a recurrent tumor was detected in S5/8-7 of the liver. Although chemotherapy with TS-1 plus Lentinan was administered, the liver tumor increased in size. Percutaneous transhepatic portal embolization was performed to improve liver function followed by resection of the right lobe of the liver. Paclitaxel plus doxifluridine (5'-DFUR) was administered for 6 months as adjuvant chemotherapy. No recurrence was observed for 17 months after hepatectomy.
- 1 August 2014
- Vol. 34 (8) , 4201-5
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
We previously reported a phase I study of a cancer vaccine using five novel HLA-A*2402-restricted peptides, and demonstrated the safety and the promising potential of our five-peptide cocktail for advanced colorectal cancer. The objective of this analysis was to investigate predictive biomarkers for the prior selection of patients who are likely to have clinical benefit from such therapy. Seventeen patients with colorectal cancer who were treated with the five peptides underwent a complete blood count, serum chemistry tests and enzyme-linked ImmunoSpot assay before the treatment as predictive markers of high reactivity to the peptides. Interleukin-6 level was a significant predictor for overall survival of patients treated with the peptide cocktail (p=0.017). A high neutrophil/lymphocyte ratio was likely to have some association with the poor induction of peptide-specific immune reaction. Interleukin-6 level might be a good predictive biomarker for clinical benefit of patients treated with this peptide vaccine.
- 1 August 2014
- Vol. 34 (8) , 4201-5
Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.
We previously reported a phase I study of a cancer vaccine using five novel HLA-A*2402-restricted peptides, and demonstrated the safety and the promising potential of our five-peptide cocktail for advanced colorectal cancer. The objective of this analysis was to investigate predictive biomarkers for the prior selection of patients who are likely to have clinical benefit from such therapy. Seventeen patients with colorectal cancer who were treated with the five peptides underwent a complete blood count, serum chemistry tests and enzyme-linked ImmunoSpot assay before the treatment as predictive markers of high reactivity to the peptides. Interleukin-6 level was a significant predictor for overall survival of patients treated with the peptide cocktail (p=0.017). A high neutrophil/lymphocyte ratio was likely to have some association with the poor induction of peptide-specific immune reaction. Interleukin-6 level might be a good predictive biomarker for clinical benefit of patients treated with this peptide vaccine.
- Open Access
- 19 June 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 175
Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer
We previously reported the clinical efficacy of adoptive immunotherapy (AIT) with dendritic cells (DCs) pulsed with mucin 1 (MUC1) peptide and cytotoxic T lymphocytes (CTLs). We also reported that gemcitabine (GEM) enhances anti-tumor immunity by suppressing regulatory T cells. Therefore, in the present study, we performed combination therapy with AIT and GEM for patients with unresectable or recurrent pancreatic cancer.
- 19 June 2014
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 12 (1) , 175
Open AccessAdoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer
We previously reported the clinical efficacy of adoptive immunotherapy (AIT) with dendritic cells (DCs) pulsed with mucin 1 (MUC1) peptide and cytotoxic T lymphocytes (CTLs). We also reported that gemcitabine (GEM) enhances anti-tumor immunity by suppressing regulatory T cells. Therefore, in the present study, we performed combination therapy with AIT and GEM for patients with unresectable or recurrent pancreatic cancer.
- 1 November 2013
- Vol. 40 (12) , 1756-8
[A resected case of hilar cholangiocarcinoma treated with neoadjuvant chemoradiation therapy].
The patient was a 69-year-old woman with elevated levels of hepatobiliary enzymes. An abdominal computed tomography (CT) scan revealed an enhanced mass in the liver hilum with dilatation of the intrahepatic bile duct. We diagnosed hilar cholangiocarcinoma and administered neoadjuvant chemoradiation therapy because of the possibility of tumor cells remaining at the surgical margins. Radical surgery was performed and pathological examination showed the tumor to be Grade 2b according to the Oboshi-Shimosato classification. Although postoperative bile leakage and intra-abdominal abscess were observed, the patient was discharged on day 82 after surgery. The patient is still alive without recurrence at 17 months after the surgery. Neoadjuvant chemoradiation therapy has the potential to obtain a negative surgical margin in patients with hilar cholangiocarcinoma, which is likely to be positive for cancer cells at the surgical margin in preoperative diagnosis.
- 1 November 2013
- Vol. 40 (12) , 1756-8
[A resected case of hilar cholangiocarcinoma treated with neoadjuvant chemoradiation therapy].
The patient was a 69-year-old woman with elevated levels of hepatobiliary enzymes. An abdominal computed tomography (CT) scan revealed an enhanced mass in the liver hilum with dilatation of the intrahepatic bile duct. We diagnosed hilar cholangiocarcinoma and administered neoadjuvant chemoradiation therapy because of the possibility of tumor cells remaining at the surgical margins. Radical surgery was performed and pathological examination showed the tumor to be Grade 2b according to the Oboshi-Shimosato classification. Although postoperative bile leakage and intra-abdominal abscess were observed, the patient was discharged on day 82 after surgery. The patient is still alive without recurrence at 17 months after the surgery. Neoadjuvant chemoradiation therapy has the potential to obtain a negative surgical margin in patients with hilar cholangiocarcinoma, which is likely to be positive for cancer cells at the surgical margin in preoperative diagnosis.
- 1 November 2013
- Vol. 40 (12) , 1807-9
[A case of hepatocellular carcinoma with Vp4 tumor thrombus treated by radiation therapy before hepatectomy].
A 61-year-old man who complained of right hypochondralgia was diagnosed as hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV) infection. The tumor was located in the right lobe and S3, and the tumor thrombus extended into the main portal and left portal veins. Preoperatively, real-time tumor-tracking radiation therapy was performed on the tumor thrombus (20 Gy/4 Fr),after vessel coils were placed at the anterior hepatic artery as a marker for the radiation. Ten days after radiation therapy, extended right hepatectomy with thrombectomy and S3 partial hepatectomy were performed. There were no postsurgical complications, and intrahepatic artery infusion chemotherapy was performed. The patient was alive with no recurrences 20 months after surgery. Radiation therapy before hepatectomy is an effective treatment for portal venous tumor thrombus in HCC.
- 1 November 2013
- Vol. 40 (12) , 1807-9
[A case of hepatocellular carcinoma with Vp4 tumor thrombus treated by radiation therapy before hepatectomy].
A 61-year-old man who complained of right hypochondralgia was diagnosed as hepatocellular carcinoma (HCC) associated with hepatitis B virus (HBV) infection. The tumor was located in the right lobe and S3, and the tumor thrombus extended into the main portal and left portal veins. Preoperatively, real-time tumor-tracking radiation therapy was performed on the tumor thrombus (20 Gy/4 Fr),after vessel coils were placed at the anterior hepatic artery as a marker for the radiation. Ten days after radiation therapy, extended right hepatectomy with thrombectomy and S3 partial hepatectomy were performed. There were no postsurgical complications, and intrahepatic artery infusion chemotherapy was performed. The patient was alive with no recurrences 20 months after surgery. Radiation therapy before hepatectomy is an effective treatment for portal venous tumor thrombus in HCC.